Company: PCRX
Filing Date: 2025-03-14
Form Type: DEFA14A
Source: 0001104659-25-024033
Chunk: 0

Company: Pacira BioSciences, Inc.
Filing Date: 2025-03-14
Form: DEFA14A
Chunk 0
---
<div align='center'>UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of
the Securities Exchange Act of 1934</div>

Filed by the Registrant x

Filed by a Party other than the Registrant ¨

Check the appropriate box:

| ¨ | Preliminary Proxy Statement                      |
| ¨ | Confidential, for Use of the Commission Only (as 
 permitted by Rule 14a-6(e)(2))                   |
| ¨ | Definitive Proxy Statement                       |
| ¨ | Definitive Additional Materials                  |
| x | Soliciting Material under §240.14a-12            |

<div align='center'>PACIRA BIOSCIENCES, INC.

(Name of Registrant as Specified
in Its Charter)

(Name of Person(s) Filing Proxy Statement,
if other than the Registrant)</div>

Payment of Filing Fee (Check the appropriate box):

| x | No fee required. |

| ¨ | Fee paid previously with preliminary materials. |

| ¨ | Fee computed on table in exhibit required by Item 
 25(b) per Exchange Act Rules 14a6(i)(1) and 0-11. |

On March 14, 2025, Pacira BioSciences, Inc. issued the following press release:

Pacira BioSciences Confirms Receipt of Director Nominations from DOMA Perpetual

<div align='center'>-- No Shareholder Action Required at This Time
–</div>

PARSIPPANY, N.J., March 14, 2025 (GLOBE NEWSWIRE)
-- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to
transform the lives of patients, today confirmed that DOMA Perpetual Capital Management LLC (“DOMA”) has nominated three candidates
to stand for election to the Pacira Board of Directors (the “Board”) at the Company’s 2025 Annual Meeting of Stockholders.

Pacira issued the following statement in response
to DOMA’s director nominations:

“Pacira’s Board and management team are taking decisive action to enhance shareholder value. We recently completed a comprehensive portfolio review and defined our 5x30 plan as the best plan to deliver shareholder value. The Nominating, Governance and